Publicaciones in 2022
Lara-Chica M, Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Ponce FJ, Moreno R, Morrison K, Di Vona C, Arato K, Jimenez-Jimenez C, Morrugares R, Schmitz ML, de la Luna S, de la Vega L, Calzado MA. CELL DEATH AND DIFFERENTIATION. 2022. DOI: 10.1038/s41418-021-00845-5
Climent MA, Font A, Duran I, Puente J, Mendez-Vidal MJ, Saez MI, Lobera CS, Arija JAA, Gonzalez-Del-Alba A, Sanchez-Hernandez A, Fita MJJ, Esteban E, Alonso-Gordoa T, Gonzalez BM, Maroto P, Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C, Castellano D. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.08.002
Argiles G, Mulet N, Valladares-Ayerbes M, Vieitez JM, Gravalos C, Garcia-Alfonso P, Santos C, Tobena M, Garcia-Paredes B, Benavides M, Cano MT, Loupakis F, Rodriguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E, Tabernero J. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.09.037
Garcia-Torres F, Jablonski MJ, Gomez-Solis A, Moriana JA, Jaen-Moreno M, Moreno-Diaz MJ, Aranda E. HEALTH PSYCHOLOGY REPORT. 2022. DOI: 10.5114/hpr.2021.111297
Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez MD, Sastre J, Alonso-Orduna V, Vieitez JM, Yubero A, Vera R, Asensio-Martinez E, Garcia-Alfonso P, Aranda E, Diaz-Rubio E, Perez-Villamil B. CANCER BIOMARKERS. 2022. DOI: 10.3233/CBM-210353
Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gomez-Espana A, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. CANCERS. 2022. DOI: 10.3390/cancers14133054
Herrera-Martinez Y, Gonzalez MJC, Pedraza-Arevalo S, Martinez MDG, Martinez AR, Menchen AG, Molina MAB, Galvez-Moreno MA, Moreno-Vega AL, Luque RM, Herrera-Martinez AD. FRONTIERS IN ENDOCRINOLOGY. 2022. DOI: 10.3389/fendo.2021.812385
Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-del Muro X, Alonso T, Anguera G, Suarez C, Munoz-Langa J, Villalobos-Leon L, Rodriguez-Sanchez A, Lainez N, Martinez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzman JC, Mendez-Vidal MJ, Rubio G, Garcia I, Capdevila L, Lambea J, Vazquez S, Fernandez O, Hernando-Polo S, Cerezo S, Santander C, Garcia-Marrero R, Zambrana F, Gonzalez-del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, Garcia A, Sotelo M, Arevalo MG, Garcia-Donas J, Hernandez C, Bolos MV, Llinares J, Climent MA. CLINICAL GENITOURINARY CANCER. 2022. DOI: 10.1016/j.clgc.2021.09.006
Elez E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, Ortiz-Morales MJ, Losa F, Diaz IA, Grana B, Toledano-Fonseca M, Valladares-Ayerbes M, Polo E, Salgado M, De Castro EM, Safont MJ, Salud A, Ruiz-Casado A, Tabernero J, Riesco MD, Rodriguez-Ariza A, Aranda E. BRITISH JOURNAL OF CANCER. 2022. DOI: 10.1038/s41416-021-01638-w
Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. TRIALS. 2022. DOI: 10.1186/s13063-022-06731-w
Garcia-Torres F, Gomez-Solis A, Garcia SR, Castillo-Mayen R, Ruiz-Ruano VG, Moreno E, Moriana JA, Luque-Salas B, Jaen-Moreno MJ, Cuadrado-Hidalgo F, Galvez-Lara M, Jablonski M, Rodriguez-Alonso B, Aranda E. FRONTIERS IN PSYCHOLOGY. 2022. DOI: 10.3389/fpsyg.2022.871929
Pedraza-Arevalo S, Ibanez-Costa A, Blazquez-Encinas R, Branco MR, Vazquez-Borrego MC, Herrera-Martinez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sanchez A, Galvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castano JP. MOLECULAR ONCOLOGY. 2022. DOI: 10.1002/1878-0261.13107
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. EUROPEAN UROLOGY. 2022. DOI: 10.1016/j.eururo.2022.04.013
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang JY, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. LANCET ONCOLOGY. 2022. DOI: 10.1016/S1470-2045(22)00212-1
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini R, He CS, Mody K, Cella D. ONKOUROLOGIYA. 2022. DOI: 10.17650/1726-9776-2022-18-2-39-57
Porta VG, Camps C, Duran MAC, Gallardo E, del Alba AG, Lazaro-Quintela M, Vidal MJM, Marin AP, Puente J, Anton-Rodriguez C, Caballero-Martinez F, Campos-Lucas FJ, Lugo I, Rogado A, Duran I. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-021-02703-9
Gil-Guillen VF, Balsa A, Bernardez B, Llorca CVY, Marquez-Contreras E, de la Haba-Rodriguez J, Castellano JM, Gomez-Martinez J. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2022. DOI: 10.3390/ijerph191912036
Montes AF, Elez E, Vivancos A, Martinez N, Gonzalez P, Covela M, de la Camara J, Cousillas A, Mendez JC, Grana B, Aranda E. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-021-02767-7
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, De La Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.03.006
Albanell J, Perez-Garcia JM, Gil-Gil M, Curigliano G, Ruiz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AM, Quiroga V, Bertran AS, Mina L, Bellosillo B, Rojo F, Menendez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortes J, Llombart-Cussac A. CLINICAL CANCER RESEARCH. 2022. DOI: 10.1158/1078-0432.CCR-22-1281
Albanell J, Martinez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela JA, de la Haba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-Munoz A, Anton A, Casas M, Bezares S, Rojo F. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2021.11.010
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, Garcia-Donas J, Rodriguez MG, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuellar-Rivas MA, Rodriguez-Alonso RM, Rodriguez-Moreno JF, Suarez-Rodriguez C. ESMO OPEN. 2022. DOI: 10.1016/j.esmoop.2022.100463
Bofill JS, Anton FM, Sanchez CAR, Calvo EG, Melia CH, Gil EMC, Vidal M, Jimenez-Rodriguez B, Merino LD, Janez NM, Vazquez RV, Salas RD, Torres AA, Lopez IMA, Gregori JG, Garcia VQ, Rubio EV, De la Haba-Rodriguez J, Gonzalez-Santiago S, Fernandez ND, Molins AB, De Ibarguen BCS, Mingorance JID, Ezquerra MB, De Casa S, Gimeno A, Martin M. BREAST. 2022. DOI: 10.1016/j.breast.2022.09.006
Herrera-Martinez Y, Teomiro CA, Idougourram SL, Puertas MJM, Continente AC, Blanch RS, Castano JP, Moreno MAG, Gahete MD, Luque RM, Herrera-Martinez AD. CANCERS. 2022. DOI: 10.3390/cancers14010111
Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-022-02816-9
de la Haba-Rodriguez J, Lloret FF, Salgado MAV, Arce MO, Gutierrez AC, Jimenez JGD, Zambrano CB, Alonso RMR, Lopez RL, Salas NR. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-022-02817-8
Perez-de-Villar J, Arjona-Sanchez A, Rufian-Andujar B, Valenzuela-Molina F, Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Casado-Adam A, Viyuela-Garcia C, Rufian-Pena S, Caro-Cuenca T, Moreno-Vega A, Briceno-Delgado J. CIRUGIA ESPANOLA. 2022. DOI: 10.1016/j.ciresp.2021.05.001
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. MOLECULAR ONCOLOGY. 2022. DOI: 10.1002/1878-0261.13141
Ciria R, Ayllon MD, Padial A, Gomez-Serrano J, Garcia-Gaitan C, Gomez-Espana A, Espejo JJ, Briceno J. ANNALS OF SURGICAL ONCOLOGY. 2022. DOI: 10.1245/s10434-021-11005-x
Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MD, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Bernabe R, Vinolas N, Aranda IB, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022. DOI: 10.1136/jitc-2022-005320
Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez CG, Vieitez JM, Rivera F, Safont MJ, Abad A, Sastre J, Valladares-Ayerbes M, Carrato A, Gonzalez-Flores E, Robles L, Salud A, Alonso-Orduna V, Montagut C, Asensio E, Diaz-Rubio E, Aranda E. EJSO. 2022. DOI: 10.1016/j.ejso.2021.11.122
Publicaciones en 2021
Garcia-Ortiz MV, De La Torre-Aguilar MJ, Morales-Ruiz T, Gomez-Fernandez A, Flores-Rojas K, Gil-Campos M, Martin-Borreguero P, Ariza RR, Roldan-Arjona T, Perez-Navero JL. Analysis of Global and Local DNA Methylation Patterns in Blood Samples of Patients With Autism Spectrum Disorder. FRONTIERS IN PEDIATRICS. 202 9():-. DOI: 10.3389/fped.202685310.
IF: 3,418 Q1 D2
Perez-Sanchez C, Barbarroja N, Pantaleao LC, Lopez-Sanchez LM, Ozanne SE, Jurado-Gamez B, Aranda E, Lopez-Pedrera C, Rodriguez-Ariza A. Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer. JOURNAL OF PERSONALIZED MEDICINE. 2021. 11(2):-. DOI: 10.3390/jpm11020111.
IF: 4,945 Q1 D2
Vera R, Salgado M, Safont MJ, Gallego J, Gonzalez E, Elez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(4):827-839. DOI: 10.1007/s12094-020-02475-8.
IF: 3,405 Q3
Garcia-Alfonso P, Munoz A, Jimenez-Castro J, Jimenez-Fonseca P, Pericay C, Longo-Munoz F, Reyna-Fortes C, Argiles-Martinez G, Gonzalez-Astorga B, Gomez-Reina MJ, Ruiz-Casado A, Rodriguez-Salas N, Lopez-Lopez R, Carmona-Bayonas A, Conde-Herrero V, Aranda E. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. CANCERS. 2021. 13(18):-. DOI: 10.3390/cancers1318451
IF: 6,639 Q1 D3
Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales MJ, Mozo JLM, Munoz A, Duran G, Sastre J, Safont MJ, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez JM, Yubero A, Aranda E. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. DRUGS & AGING. 2021. 38(3):219-231. DOI: 10.1007/s40266-021-00834-w.
IF: 3,923 Q2 D5
Guil-Luna S, Sedlik C, Piaggio E. Humanized Mouse Models to Evaluate Cancer Immunotherapeutics. ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021. 2021. 5():119-13 DOI: 10.1146/annurev-cancerbio-050520-100526.
IF: 9,391 Q1 D2
Manzanares-Martin B, Aranda AC, del Puerto-Nevado L, Gonzalez R, Solanes S, Gomez-Espana MA, Garcia-Foncillas J, Aranda E. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021. 9(4):-. DOI: 10.1136/jitc-2020-001705.
IF: 13,751 Q1 D1
Lopez-Sanchez LM, Mena R, Guil-Luna S, Mantrana A, Penarando J, Toledano-Fonseca M, Conde F, De La Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. LABORATORY INVESTIGATION. 2021. 101(3):292-303. DOI: 10.1038/s41374-020-00507-z.
IF: 5,662 Q1 D2
Gomez-Espana MA, Montes AF, Garcia-Carbonero R, Mercade TM, Maurel J, Martin AM, Pazo-Cid R, Vera R, Carrato A, Feliu J. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):988-1000. DOI: 10.1007/s12094-021-02573-1.
IF: 3,405 Q3 D
Toledano-Fonseca M, Cano MT, Inga E, Gomez-Espana A, Guil-Luna S, Garcia-Ortiz MV, Mena-Osuna R, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer. CANCERS. 2021. 13(6):-. DOI: 3390/cancers13061210.
IF: 6,639 Q1 D3
Garcia-Carmona M, Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Moriana JA, Moreno-Diaz MJ, Aranda E. The influence of family social support on quality of life of informal caregivers of cancer patients. NURSING OPEN. 2021. 8(6):3411-3419. DOI: 10.1002/nop2.887.
IF: 1,762 Q3
Alors-Perez E, Blazquez-Encinas R, Alcala S, Viyuela-Garcia C, Pedraza-Arevalo S, Herrero-Aguayo V, Jimenez-Vacas JM, Mafficini A, Sanchez-Frias ME, Cano MT, Abollo-Jimenez F, Marin-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sanchez L, Sanchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibanez-Costa A, Sainz B, Luque RM, Castano JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 202 40(1):-. DOI: 10.1186/s13046-021-02153-9.
IF: 11,161 Q1 D1
Sastre J, Garcia-Alfonso P, Vieitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Diaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martinez E, Garcia-Paredes B, Lopez RL, Guillot M, Valladares-Ayerbes M, Aranda E, Diaz-Rubio E. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study. ESMO OPEN. 2021. 6(2):-. DOI: 10.1016/j.esmoop.2021.10006
IF: 6,54 Q1 D3
Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Munoz E, Rodriguez-Serrano EM, Avila JCM, Salinas-Munoz L, Serrano-Huertas S, Ferreiro R, Rodriguez-Garrote M, Sainz B, Massuti B, Alfonso PG, Benavides M, Aranda E, Garcia-Bermejo ML, Carrato A. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. CANCERS. 2021. 13(7):-. DOI: 10.3390/cancers13071710.
IF: 6,639 Q1 D3
Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021. 9(8):-. DOI: 10.1136/jitc-2021-00280
IF: 13,751 Q1 D1
Taieb J, Aranda E, Raouf S, Dunn H, Arnold D. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2021. 20(1):42-51. DOI: 10.1016/j.clcc.2020.10.00
IF: 4,481 Q2 D5
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Aranda IB, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. LUNG CANCER. 2021. 161():76-85. DOI: 10.1016/j.lungcan.2021.09.002.
IF: 5,705 Q1 D3
Dols MC, Zambrano CB, Gutierrez LC, Sett RC, Lopez-Barajas MIB, Navalon FG, Perez JLF, Bermudez GS, Torres PT, Mingorance ID, Marin AG, Oriol AL, Lario AP, Maurino PS, Gomez OH, Munoz DM, Lopez AJJ, Gonzalez IH, Yague AS, Lopez BS. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. BMJ SUPPORTIVE & PALLIATIVE CARE. 2021. 11(1):25-31. DOI: 10.1136/bmjspcare-2020-002249.
IF: 3,568 Q2 D4
Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, Garcia-Corbacho J, Garcia-Mata J, Jara C, Jerez JM, Lazaro-Quintela M, Leon-Mateos L, Ramirez-Merino N, Tibau A, Garcia-Palomo A. Electronic health records and patient registries in medical oncology departments in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(10):2099-210 DOI: 10.1007/s12094-021-02614-9.
IF: 3,405 Q3 D
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Gordoa TA, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing DY, Choueiri TK. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE. 2021. 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. IF: 91,245 Q1 D1
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Casas M, Csoszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, Lopez IA, Gal-Yam E, Garcia-Palomo A, Alvarez E, Gonzalez-Santiago S, Rodriguez CA, Servitja S, Corsaro M, Rodrigalvarez G, Zielinski C, Martin M. Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. EUROPEAN JOURNAL OF CANCER. 2021. 156():70-82. DOI: 1016/j.ejca.2021.07.004.
IF: 9,192 Q1 D2
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csoszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Bartlett CH, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Saenz JA, Chacon JI, Swift C, Thallinger C, Gil-Gil M. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. ANNALS OF ONCOLOGY. 2021. 32(4):488-499. DOI: 10.1016/j.annonc.2020.12.013.
IF: 32,976 Q1 D1
Astorga BG, Ballabrera FS, Aguilar EA, Fernandez EE, Garcia-Alfonso P, Flores EG, Garcia RV, Montes AF, Munoz AML, Salvia AS. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(8):1520-1528. DOI: 10.1007/s12094-021-02568-y.
IF: 3,405 Q3
Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, de Castro EM, Gallego J, Limon ML, Alsina M, Lopez L, Galan M, Falco E, Manzano JL, Gonzalez E, Munoz-Unceta N, Lopez C, Aranda E, Fernandez E, Jorge M, Jimenez-Fonseca P. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. EUROPEAN JOURNAL OF CANCER. 2021. 145():158-167. DOI: 10.1016/j.ejca.2020.12.005.
IF: 9,162 Q1 D2
Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Campelo MDG, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021. 27(21):5878-5890. DOI: 10.1158/1078-0432.CCR-21-1200.
IF: 12,531 Q1 D1
Sartore-Bianchi A, Garcia-Alfonso P, Geissler M, Kohne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2021. 20(4):305-313. DOI: 10.1016/j.clcc.2021.05.007.
IF: 4,481 Q2 D5
Ferre AD, Alvarez RA, Herraez AC, Jurado JC, Gonzalez AE, Martin-Broto J, Marin VM, Vega AM, Garcia AS, Morales CV. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):922-930. DOI: 10.1007/s12094-020-02534-0.
IF: 3,405 Q3
del Alba AG, Mendez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):969-979. DOI: 10.1007/s12094-021-02561-5.
IF: 3,405 Q3
Gil-Gil M, Alba E, Gavila J, de la Haba-Rodriguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A. The role of CDK4/6 inhibitors in early breast cancer. BREAST. 2021. 58():160-169. DOI: 10.1016/j.breast.2021.05.008.
IF: 4,38 Q1 D2
Szabados B, Rodriguez-Vida A, Duran I, Crabb SJ, Van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal MJ, Suarez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. EUROPEAN UROLOGY ONCOLOGY. 2021. 4(3):456-463. DOI: 10.1016/j.euo.2020.11.010.
IF: 7,479 Q1 D1
Ruedas-Torres I, Rodriguez-Gomez IM, Sanchez-Carvajal JM, Guil-Luna S, Larenas-Munoz F, Pallares FJ, Carrasco L, Gomez-Laguna J. Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion. FRONTIERS IN IMMUNOLOGY. 2021. 12():-. DOI: 10.3389/fimmu.2021.671743. IF: 7,561 Q1 D2
Camps C, López R, Antón A, Aranda E, Carrato A, Cruz JJ, Cunquero-Tomás AJ, Díaz-Rubio E, Feyjóo M, García-Foncillas J, Gascón P, Lugo I, Rogado Á, Guillem V. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. JCO Oncol Pract. 2021 Feb 23:OP2000683. doi: 10.1200/OP.20.00683. EAC: LA INCLUYE EL GRUPO. OK
IF: 3,487 Q3
Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP, Gonzalez-Martin A.
SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021 May;23(5):961-968. doi: 10.1007/s12094-020-02545-x. EAC: LA INCLUYE EL GRUPO. OK
FI: 2,737 Q3
Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021; 14: 72. doi: 10.1186/s13048-021-00816-x EAC: LA INCLUYE EL GRUPO. OK
FI: 6,923 Q1
J.A. Perez-Fidalgo, A. Cortés, E. Guerra, Y. García, M. Iglesias, U. Bohn Sarmiento, E. Calvo García, L. Manso Sánchez, A. Santaballa, A. Oaknin, A. Redondo, M.J. Rubio, A. González-Martín. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open. 2021 Aug; 6(4): 100212. doi: 10.1016/j.esmoop.2021.100212. EAC: LA INCLUYE EL GRUPO. OK
FI: 5,329 Q1
Publicaciones 2020
Guil-Luna S, Mena R, Navarrete-Sirvent C, Lopez-Sanchez LM, Khouadri K, Toledano-Fonseca M, Mantrana A, Guler I, Villar C, Diaz C, Medina-Fernandez FJ, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A,. Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. FRONTIERS IN MEDICINE. 2020. 7 ():- DOI: 10.3389/fmed.2020.00264
IF: 3,9 Q: 1
Gavila J, De La Haba J, Bermejo B, Rodriguez-Lescure A, Anton A, Ciruelos E, Brunet J, Munoz-Couselo E, Santisteban M, Sanchez CAR, Santaballa A, Rovira PS, Saenz JAG, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanches A, Romera JL, Aguirre E, Co. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (3):420-428 DOI: 10.1007/s12094-019-02145-4
IF: 2,737 Q: 3
Sastre J, de la Orden V, Martinez A, Bando I, Balbin M, Bellosillo B, Palanca S, Gomez MIP, Mediero B, Llovet P, Moral VM, Vieitez JM, Garcia-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Diaz-Rubio E, Aranda E. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naive Metastatic Colorectal Cancer Patients Prospectively Collected. CLINICAL COLORECTAL CANCER. 2020. 19 (3):E110-E116 DOI: 10.1016/j.clcc.2020.02.014
IF: 3,245 Q: 3
Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodriguez-Vida A, Lainez N, Villatoro R, Llacer C, Cattrini C, Hernandez A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, Lopez-Campos F, Gonzalez B, Mendez-Vidal MJ, Medina A, Piulats J. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. EUROPEAN UROLOGY. 2020. 77 (6):763-766 DOI: 10.1016/j.eururo.2020.02.025
IF: 17,947 Q: 1 D: 1
Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. JAMA NETWORK OPEN. 2020. 3 (10):- DOI: 10.1001/jamanetworkopen.2020.20425
IF: 5,032 Q: 1
Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Galvez-Lara M, Moriana JA, Moreno-Diaz MJ, Aranda E. Caregiver Burden Domains and Their Relationship with Anxiety and Depression in the First Six Months of Cancer Diagnosis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020. 17 (11):- DOI: 10.3390/ijerph17114101
IF: 2,849 Q: 1
Toledano-Fonseca M, Cano MT, Inga E, Rodriguez-Alonso R, Gomez-Espana MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. CANCERS. 2020. 12 (7):- DOI: 10.3390/cancers12071754
IF: 6,126 Q: 1
Fernandez-Montes A, Gravalos C, Pericay C, Safont MJ, Benavides M, EElez E, Garcia-Alfonso P, Garcia-Paredes B, Carrato A, Aranda E. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. CLINICAL COLORECTAL CANCER. 2020. 19 (3):165-177 DOI: 10.1016/j.clcc.2020.04.003
IF: 3,245 Q: 3
Puente J, Anido U, Climent MA, Gonzalez-Billalabeitia E, Lainez N, Lambea J, Maroto JP, Mendez-Vidal MJ, Montesa A, Rodriguez A, Zambrana C, Gonzalez-del-Alba A. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2020. 12 ():- DOI: 10.1177/1758835920920067
IF: 6,852 Q: 1
Aranda E, Vieitez JM, Gomez-Espana A, Calle SG, Salud-Salvia A, Grana B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, Gonzalez-Flores E, Fernandez MS, Guillen-Ponce C, Garcia-Carbonero R, Safont MJ, Munoa AL, Garcia-Paredes B, Lopez RL, Sastre J, Diaz-Rubio E. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial. ESMO OPEN. 2020. 5 (6):- DOI: 10.1136/esmoopen-2020-000944
IF: 5,329 Q: 1
Perez-Ruiz E, Jimenez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, Toscano F, Artacho MRD, Garrido-Siles M, Martinez-Bautista MJ, Roldan RV, Rivas-Ruiz F, Nogales-Fernandez E, Morales C, Perez-Valderrama B, De la Cruz-Merino L, Rueda A. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (10):1778-1785 DOI: 10.1007/s12094-020-02315-9
IF: 2,737 Q: 3
Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farres J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R, Oliva B, Mas JM. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLOS ONE. 2020. 15 (10):- DOI: 10.1371/journal.pone.0240149
IF: 2,74 Q: 2
Gonzalez-del-Alba A, Arranz JA, Bellmunt J, Maroto JP, Fernandez-Calvo O, Valderrama BP, Gonzalez-Billalabeitia E, Mendez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MA, Puentel J, Pelaez I, Lazaro-Quintela M, Gallardo E, Suarez C. Latest progress in molecular biology and treatment in genitourinary tumours. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (12):2175-2195 DOI: 10.1007/s12094-020-02373-z
IF: 2,737 Q: 3
Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton CS, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2020. 21 (11):1413-1422 DOI: 10.1016/S1470-2045(20)30453-8
IF: 33,752 Q: 1 D: 1
Lopez-Sanchez LM, Aranda E, Rodriguez-Ariza A. Nitric oxide and tumor metabolic reprogramming. BIOCHEMICAL PHARMACOLOGY. 2020. 176 ():- DOI: 10.1016/j.bcp.2019.113769
IF: 4,96 Q: 1 D: 1
Viudez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernandez R, Cano JM, Macias I, Custodio A, de Castro EM, Sanchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sanchez-Canovas M, Mangas M, Limon ML, Martinez-Torron A, Asensio E, Ramchandani A, Martin-Carnicero, A (Martin-Carnicero, A.)[ 20 ] ; Hurtado, A (Hurtado, A.)[ 21 ] ; Cerda, P (Cerda, P.)[ 22 ] ; Garrido, M (Garrido, M.)[ 23 ] ; Sanchez-Bayonas, R (Sanchez-Bayonas, R.)[ 24 ] ; Serrano, R (Serrano, R.)[ 25 ] ; Jimenez-Fonseca, P (Jimenez-Fonseca, P.)[ 26 ] . Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (5):734-750 DOI: 10.1007/s12094-019-02183-y
IF: 2,737 Q: 3
Carrato A, Vieitez JM, Benavides M, Rodriguez-Garrote M, Castillo A, Ogalla GD, Bermejo LG, de Mena IR, Guillen-Ponce C, Aranda E. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. EUROPEAN JOURNAL OF CANCER. 2020. 139 ():51-58 DOI: 10.1016/j.ejca.2020.07.035
IF: 7,275 Q: 1
Salazar R, Capdevila J, Manzano JL, Pericay C, Martinez-Villacampa M, Lopez C, Losa F, Safont MJ, Gomez-Espana A, Alonso-Orduna V, Escudero P, Gallego J, Garcia-Paredes B, Palacios A, Biondo S, Gravalos C, Aranda E. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC CANCER. 2020. 20 (1):- DOI: 10.1186/s12885-020-07661-z
IF: 3,15 Q: 3
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz JA, Torres R, de la Haba J, Garcia-Martinez E, Gomez HL, Llombart A, Bofill JS, Baena-Canada JM, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernande. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38 (3):203-213 DOI: 10.1200/JCO.19.00904
IF: 32,956 Q: 1 D: 1
Lazaro M, Valderrama BP, Suarez C, de-Velasco G, Beato C, Chirivella I, Gonzalez-Del-Alba A, Lainez N, Mendez-Vidal MJ, Arranz JA. SEOM clinical guideline for treatment of kidney cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):256-269 DOI: 10.1007/s12094-019-02285-7
IF: 2,737 Q: 3
Guillen-Ponce C, Lastra E, Lorenzo-Lorenzo I, Gomez TM, Chamorro RM, Sanchez-Heras AB, Serrano R, Rodriguez MCS, Soto JL, Robles L. SEOM clinical guideline on hereditary colorectal cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):201-212 DOI: 10.1007/s12094-019-02272-y
IF: 2,737 Q: 3
Gallardo E, Medina J, Sanchez JC, Viudez A, Grande E, Porras I, Ramon y Cajal T, Trigo J, Iglesias L, Capdevila J. SEOM clinical guideline thyroid cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):223-235 DOI: 10.1007/s12094-019-02284-8
IF: 2,737 Q: 3
Garcia-Torres F, Jablonski MJ, Solis AG, Moriana JA, Jaen-Moreno MJ, Moreno-Diaz MJ, Aranda E. Social support as predictor of anxiety and depression in cancer caregivers six months after cancer diagnosis: A longitudinal study. JOURNAL OF CLINICAL NURSING. 2020. 29 (5-6):996-1002 DOI: 10.1111/jocn.15123
IF: 1,972 Q: 1
Rodriguez-Lescure A, de la Pena FA, Aranda E, Calvo A, Felip E, Garrido P, Vera R. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (12):2253-2263 DOI: 10.1007/s12094-020-02366-y
IF: 2,737 Q: 3
de las Heras BB, Cajal JCRY, Calvo EG, Rodriguez JD, Mata JG, Anton FM, Fernandez IP, Rodriguez-Lescure A, Sanchez CAR, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Alvarez JS. The economic burden of metastatic breast cancer in Spain. EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE. 2020. 27 (1):19-24 DOI: 10.1136/ejhpharm-2017-001453
IF: 0,892 Q: 4
Aranda E, Polo E, Camps C, Carrato A, Diaz-Rubio E, Guillem V, Lopez R, Anton A. Treatment patterns for metastatic colorectal cancer in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (9):1455-1462 DOI: 10.1007/s12094-019-02279-5
IF: 2,737 Q: 3
Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Morrugares R, Munoz E, Calzado MA. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases. CELLULAR AND MOLECULAR LIFE SCIENCES. 2020. 77 (23):4747-4763 DOI: 10.1007/s00018-020-03556-1
IF: 6,496 Q: 1
Publicaciones 2019
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S. Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 9. DOI:10.1002/mnfr.201800864.
IF: 5,151 D: 1
Penarando J, Aranda E, Rodriguez-Ariza A. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response. TRANSLATIONAL RESEARCH. 2019. 210. 99-108. DOI:10.1016/j.trs1.2019.03.003.
IF: 4,915 D: 1
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 2019. 121. 5. 378-383. DOI:10.1038/s41416-019-0537-z.
IF: 5,416 Q: 1
Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. . 0. DOI:10.1111/jcmm.14693.
IF: 4,658 Q: 1
Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 2019. 19. DOI:10.1186/s12885-019-5753-7.
IF: 2,933 Q: 3
Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 2019. 21. 1. 46-54. DOI:10.1007/s12094-018-02002-w.
IF: 2,441 Q: 3
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J. Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2019. 19. 11. 1388-1398. DOI:10.2174/1871520619666190417162409.
IF: 2,18 Q: 3
Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. CLINICAL DRUG INVESTIGATION. 2019. 39. 7. 595-606. DOI:10.1007/s40261-019-00790-9.
IF: 1,918 Q: 3
Publicaciones 2018
Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018; 29(2):439-444.
IF: 13,926 Q: 1 D: 1
Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018; 16:Núm artículo 3
IF: 5,77 Q: 1 D: 1
Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018; 101:263-272.
IF: 7,191 Q: 1
Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018; 23(11):1271-e128.
IF: 5,306 Q: 1
Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Tabernero J, Giralt J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2018; 13(1):69-78.
IF: 3,877 Q: 2
De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. TRENDS IN IMMUNOLOGY. 2018; 39(9):748-763.
IF: 14,188 Q: 1 D: 1
Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2018; 17(2):E323-E329.
IF: 3,861 Q: 2
Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilar EA. Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. MEDICINE; 2018:97(17):Núm artículo e0098
IF: 2,028 Q: 2
Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC PHARMACOLOGY & TOXICOLOGY. 2018; 19:Núm artículo 77
IF: 1,865 Q: 3
Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer. MEDICINA CLINICA. 2018; 151(3):97-102.
IF: 1,168 Q: 3
Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(5):613-618.
IF: 2,392 Q: 3
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(28):2826-2835.
IF: 26,303 Q: 1 D: 1
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018; 110(6):638-648.
IF: 11,238 Q: 1 D: 1
Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 103:205-213.
IF: 7,191 Q: 1
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 91:99-106.
IF: 7,191 Q: 1
Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER. 2018; 119(12):1464-1470.
IF: 5,922 Q: 1
Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLOS ONE. 2018; 13(4):Núm artículo e0194844
IF: 2,766 Q: 1
Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC CANCER 2018; 18:Núm artículo 106
IF: 3,288 Q: 2
Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC CANCER. 2018; 18:Núm artículo 183
IF: 3,288 Q: 2
Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Llinares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. EXPERT OPINION ON DRUG SAFETY. 2018; 17(6):573-579.
IF: 3,156 Q: 2
Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. CLINICAL GENITOURINARY CANCER. 2018; 16(6):E1133-E1139.
IF: 2,539 Q: 2
Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(10):1337-1344.
IF: 2,392 Q: 3
Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C. SEOM clinical guideline for treatment of kidney cancer (2017). CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(1):47-56.
IF: 2,392 Q: 3
Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernando S, Leon L, del Alba AG, Lainez N, Esteban E, Reynes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. FUTURE ONCOLOGY. 2018; 14(1):41-50.
IF: 2,369 Q: 3
Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. MEDICINA CLINICA. 2018; 150(1):1-7.
IF: 1,168 Q: 3
